+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alprazolam Market by Type and Geography - Forecast and Analysis 2020-2024 - Product Image

Alprazolam Market by Type and Geography - Forecast and Analysis 2020-2024

  • ID: 4876572
  • Report
  • November 2019
  • Region: Global
  • 159 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Alprazolam Market: About this market
The alprazolam market analysis considers sales of alprazolam in Asia, Europe, North America, and ROW. In 2019, the anxiety segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising number of campaigns to raise awareness about anxiety will play a significant role in the anxiety segment to maintain its market position. Also, our global alprazolam market report looks at factors such as increased drug dependency associated with the use of alprazolam, increasing prevalence of anxiety and panic disorders, and low cost of drugs. However, stringent regulatory policies, adverse side effects, and social stigma associated with anxiety and panic disorders may hamper the growth of the alprazolam industry over the forecast period.

Global Alprazolam Market: Overview

Increasing prevalence of anxiety and panic disorders
The global alprazolam market is expected to benefit significantly from the strong prevalence of psychiatric indications such as anxiety and panic disorders. The increasing number of campaigns focusing on raising awareness about the severity of anxiety and panic disorders is expected to boost the demand for drugs for the treatment of such indications The prevalence of anxiety and panic disorders is also on the rise in the younger population due to changing lifestyles and increasing stress. As per a study conducted by the NIHI(National Institute of Health), panic disorders are prevalent in approximately 2.9% of the adult population in the US, with the prevalence rate being significantly higher in women than in men. Such factors will lead to the expansion of the global alprazolam market at a CAGR of over 4% during the forecast period.

Use of alprazolam in new research areas
The use of alprazolam was strictly limited to treat anxiety and panic disorders. However, with the growing demand for novel therapeutics for various indications, the research on alprazolam as a potential treatment option for other indications is increasing. Clinical-stage pharmaceutical vendors are collaborating to research alprazolam for the treatment of epilepsy. These vendors are focusing on developing Staccato Alprazolam as a Rapid Epileptic Seizure Termination (REST) therapy for providing relief from acute repetitive seizures. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global alprazolam market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alprazolam manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.

Also, the alprazolam market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Anxiety - Market size and forecast 2019-2024
  • Panic disorders - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Drug reformulations
  • Use of alprazolam in new research areas
  • Increasing geriatric population prone to anxiety
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key product offerings
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Type - Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Anxiety - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Anxiety - Year-over-year growth 2020-2024 (%)
Exhibit 22: Panic disorders - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Panic disorders - Year-over-year growth 2020-2024 (%)
Exhibit 24: Others - Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Others - Year-over-year growth 2020-2024 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2019-2024 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 31: North America - Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Growth of geriatric population 2009-2018 (%)
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Amneal Pharmaceuticals Inc. - Vendor overview
Exhibit 52: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 53: Amneal Pharmaceuticals Inc. - Organizational developments
Exhibit 54: Amneal Pharmaceuticals Inc. - Segment focus
Exhibit 55: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 56: Amneal Pharmaceuticals Inc. - Key customers
Exhibit 57: Cadila Healthcare Ltd. - Vendor overview
Exhibit 58: Cadila Healthcare Ltd. - Business segments
Exhibit 59: Cadila Healthcare Ltd. - Organizational developments
Exhibit 60: Cadila Healthcare Ltd. - Geographic focus
Exhibit 61: Cadila Healthcare Ltd. - Key offerings
Exhibit 62: Cadila Healthcare Ltd. - Key customers
Exhibit 63: Endo International Plc - Vendor overview
Exhibit 64: Endo International Plc - Business segments
Exhibit 65: Endo International Plc - Organizational developments
Exhibit 66: Endo International Plc - Geographic focus
Exhibit 67: Endo International Plc - Segment focus
Exhibit 68: Endo International Plc - Key offerings
Exhibit 69: Endo International Plc - Key customers
Exhibit 70: Jazz Pharmaceuticals Plc - Vendor overview
Exhibit 71: Jazz Pharmaceuticals Plc - Business segments
Exhibit 72: Jazz Pharmaceuticals Plc - Organizational developments
Exhibit 73: Jazz Pharmaceuticals Plc - Geographic focus
Exhibit 74: Jazz Pharmaceuticals Plc - Key offerings
Exhibit 75: Jazz Pharmaceuticals Plc - Key customers
Exhibit 76: Mylan NV - Vendor overview
Exhibit 77: Mylan NV - Product segments
Exhibit 78: Mylan NV - Organizational developments
Exhibit 79: Mylan NV - Geographic focus
Exhibit 80: Mylan NV - Segment focus
Exhibit 81: Mylan NV - Key offerings
Exhibit 82: Mylan NV - Key customers
Exhibit 83: Novartis AG - Vendor overview
Exhibit 84: Novartis AG - Business segments
Exhibit 85: Novartis AG - Organizational developments
Exhibit 86: Novartis AG - Geographic focus
Exhibit 87: Novartis AG - Segment focus
Exhibit 88: Novartis AG - Key offerings
Exhibit 89: Novartis AG - Key customers
Exhibit 90: Pfizer Inc. - Vendor overview
Exhibit 91: Pfizer Inc. - Business segments
Exhibit 92: Pfizer Inc. - Organizational developments
Exhibit 93: Pfizer Inc. - Geographic focus
Exhibit 94: Pfizer Inc. - Segment focus
Exhibit 95: Pfizer Inc. - Key offerings
Exhibit 96: Pfizer Inc. - Key customers
Exhibit 97: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 98: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 99: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 100: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 101: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 103: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 104: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 105: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 106: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 107: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 109: UCB SA - Vendor overview
Exhibit 110: UCB SA - Business segments
Exhibit 111: UCB SA - Organizational developments
Exhibit 112: UCB SA - Geographic focus
Exhibit 113: UCB SA - Key offerings
Exhibit 114: UCB SA - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies as the key players in the global alprazolam market: Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the use of alprazolam in new research areas.”

According to the report, one of the major drivers for this market is the increasing prevalence of anxiety and panic disorders.

Further, the report states that one of the major factors hindering the growth of this market is the stringent regulatory policies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Endo International Plc
  • Jazz Pharmaceuticals Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA.
Note: Product cover images may vary from those shown
Adroll
adroll